Financial Performance - The company's operating revenue for the reporting period reached ¥270,466,229.83, representing a year-on-year increase of 19.54%[2] - The net profit attributable to shareholders of the listed company was ¥49,638,554.92, reflecting a year-on-year growth of 2.19%[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 35.87% to ¥45,475,915.94[4] - Basic earnings per share decreased by 3.30% to ¥0.88[2] - The weighted average return on net assets (excluding non-recurring items) improved to 9.65% from 8.01%[2] Assets and Equity - The total assets at the end of the reporting period amounted to ¥561,442,070.59, up 5.26% from the beginning of the period[3] - The equity attributable to shareholders of the listed company grew by 6.22% to ¥484,138,341.50[3] - The company's share capital increased by 40% to ¥56,220,500.00 due to a stock dividend distribution[4] Strategic Focus - The company focused on expanding high-tech and high-value-added products, contributing to revenue growth[4] Cautionary Note - The financial data presented is preliminary and has not been audited, highlighting the need for caution among investors[5]
峆一药业(430478) - 2024 Q4 - 年度业绩